Mohit Manrao, SVP, Head of US Oncology at AstraZeneca, shared a post on LinkedIn:
“This post is intended for a US audience.
With new MATTERHORN data presented at ESMO last month showing promising results for patients, it’s an exciting time for innovation—and we’re proud to support the gastric cancer community this November for Gastric Cancer Awareness Month.
Many people with early-stage gastric cancer experience few or no symptoms, often leading to diagnosis at an advanced stage when treatment options become limited, and survival outcomes are impacted.
However, early detection can make all the difference: more treatment options, the potential for better outcomes, and renewed hope.
While our commitment continues year-round, this month serves as a dedicated time to reflect, support those currently living with gastric cancer, and encourage proactive conversations with those at risk.
Learn how AstraZeneca is making strides toward earlier treatment.”
More posts featuring Gastric Cancer.